Swedish Orphan Biovitrum AB (publ)

OM:SOBI Stock Report

Market Cap: SEK 109.8b

Swedish Orphan Biovitrum Valuation

Is SOBI undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SOBI when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SOBI (SEK319) is trading below our estimate of fair value (SEK1137.01)

Significantly Below Fair Value: SOBI is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for SOBI?

Other financial metrics that can be useful for relative valuation.

SOBI key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.3x
Enterprise Value/EBITDA15.7x
PEG Ratio2x

Price to Earnings Ratio vs Peers

How does SOBI's PE Ratio compare to its peers?

The above table shows the PE ratio for SOBI vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average101.6x
BIOG B BioGaia
29x7.6%SEK 11.7b
BONEX Bonesupport Holding
70.6x31.2%SEK 20.4b
CAMX Camurus
176.8x75.0%SEK 39.5b
INCY Incyte
130.1x41.1%US$12.9b
SOBI Swedish Orphan Biovitrum
51.2x25.8%SEK 109.8b

Price-To-Earnings vs Peers: SOBI is good value based on its Price-To-Earnings Ratio (51.2x) compared to the peer average (101.6x).

Price to Earnings Ratio vs Industry

How does SOBI's PE Ratio compare vs other companies in the European Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a46.0%
 n/an/an/a
No. of CompaniesPE048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a46.0%
 n/an/an/a
No more companies

Price-To-Earnings vs Industry: SOBI is expensive based on its Price-To-Earnings Ratio (51.2x) compared to the European Biotechs industry average (27.3x).

Price to Earnings Ratio vs Fair Ratio

What is SOBI's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SOBI PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio51.2x
Fair PE Ratio71.5x

Price-To-Earnings vs Fair Ratio: SOBI is good value based on its Price-To-Earnings Ratio (51.2x) compared to the estimated Fair Price-To-Earnings Ratio (71.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SOBI forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 323.80
SEK 325.27
+0.5%
8.8%SEK 370.00SEK 250.00n/a11
Sep ’25SEK 320.00
SEK 328.00
+2.5%
8.5%SEK 370.00SEK 250.00n/a11
Aug ’25SEK 278.00
SEK 328.30
+18.1%
8.9%SEK 370.00SEK 250.00n/a10
Jul ’25SEK 285.80
SEK 329.60
+15.3%
6.2%SEK 370.00SEK 285.00n/a10
Jun ’25SEK 282.40
SEK 320.00
+13.3%
9.4%SEK 370.00SEK 252.00n/a10
May ’25SEK 285.40
SEK 317.22
+11.2%
9.8%SEK 370.00SEK 252.00n/a9
Apr ’25SEK 267.20
SEK 317.70
+18.9%
9.6%SEK 370.00SEK 252.00n/a10
Mar ’25SEK 260.80
SEK 317.91
+21.9%
9.2%SEK 370.00SEK 252.00n/a11
Feb ’25SEK 278.00
SEK 316.20
+13.7%
8.0%SEK 345.00SEK 252.00n/a10
Jan ’25SEK 267.00
SEK 297.00
+11.2%
6.0%SEK 325.00SEK 252.00n/a10
Dec ’24SEK 250.60
SEK 293.00
+16.9%
7.0%SEK 325.00SEK 252.00n/a10
Nov ’24SEK 234.00
SEK 287.45
+22.8%
10.0%SEK 325.00SEK 222.00n/a11
Oct ’24SEK 223.40
SEK 285.55
+27.8%
10.0%SEK 325.00SEK 222.00n/a11
Sep ’24SEK 211.00
SEK 284.18
+34.7%
10.1%SEK 325.00SEK 222.00SEK 320.0011
Aug ’24SEK 205.80
SEK 288.27
+40.1%
9.8%SEK 325.00SEK 222.00SEK 278.0011
Jul ’24SEK 210.40
SEK 286.80
+36.3%
10.4%SEK 325.00SEK 216.00SEK 285.8010
Jun ’24SEK 212.00
SEK 285.80
+34.8%
10.6%SEK 325.00SEK 216.00SEK 282.4010
May ’24SEK 249.40
SEK 287.20
+15.2%
11.5%SEK 325.00SEK 211.00SEK 285.4010
Apr ’24SEK 241.50
SEK 269.78
+11.7%
9.6%SEK 305.00SEK 211.00SEK 267.209
Mar ’24SEK 240.40
SEK 269.78
+12.2%
9.6%SEK 305.00SEK 211.00SEK 260.809
Feb ’24SEK 230.70
SEK 253.56
+9.9%
12.5%SEK 305.00SEK 203.00SEK 278.009
Jan ’24SEK 215.70
SEK 249.10
+15.5%
11.9%SEK 295.00SEK 200.00SEK 267.0010
Dec ’23SEK 226.70
SEK 250.60
+10.5%
12.2%SEK 295.00SEK 200.00SEK 250.6010
Nov ’23SEK 206.20
SEK 250.60
+21.5%
12.2%SEK 295.00SEK 200.00SEK 234.0010
Oct ’23SEK 215.60
SEK 255.00
+18.3%
10.1%SEK 295.00SEK 203.00SEK 223.4010
Sep ’23SEK 233.00
SEK 253.33
+8.7%
9.0%SEK 280.00SEK 203.00SEK 211.009

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y